Canaccord Genuity has reduced its price target for Insulet Corporation (NASDAQ: PODD) to $435 from $450 but left its Buy recommendation intact.
The firm flagged a change in valuation assumptions as the primary reason for the cut, citing compression of the multiple applied to the Elite Med-Tech comparison group. That valuation shift was balanced against Insulet’s recent operating performance and upcoming product milestones.
Market data from InvestingPro shows Insulet trading at $258.07, which sits well below Canaccord’s revised target and suggests substantial upside to the firm’s valuation despite a reported high price-to-earnings ratio of 75.36.
Quarterly performance and drivers
Insulet reported fourth-quarter revenue of $783.8 million, a 31.2% increase year-over-year on a constant currency basis. That top-line figure exceeded Canaccord Genuity’s forecast of $772.5 million and the consensus estimate of $769.0 million.
On profitability, the company posted adjusted earnings per share of $1.55, ahead of Canaccord’s $1.45 estimate and the consensus of $1.46. Separately, the article noted that reported earnings per share were $1.44, described as slightly missing some forecasts in other reporting. The two figures reflect different measures cited in recent coverage.
Insulet’s U.S. operations were a key source of upside in the quarter, with adoption among patients with Type 2 diabetes specifically highlighted as a growth vector. The company recorded its highest number of new customer starts in both the U.S. and international markets during the period, and more than 40% of new U.S. customer starts were attributable to Type 2 patients.
Revenue breakdowns released with the results showed U.S. Omnipod revenue rose 28% year-over-year to $567.8 million, while international Omnipod revenue grew 41.7% year-over-year in constant currency to $214.0 million.
Analyst context and upcoming catalysts
Canaccord said its decision to lower the price target reflects the compressed multiple of the Elite Med-Tech comparison group rather than a change to Insulet’s near-term revenue trajectory. The firm noted forthcoming product and data catalysts that could influence the company’s valuation over time.
Specifically, Canaccord pointed to the planned 2027 commercial launch of Omnipod 6, with pivotal data expected to be presented at the American Diabetes Association conference in June. The firm also highlighted Insulet’s roadmap toward a fully closed-loop system for Type 2 diabetes, expected to begin commercial availability in 2028.
Other analyst activity and market reaction
In related coverage, BTIG reiterated a Buy rating on Insulet and maintained a price target of $380 following the quarterly results, calling out the company’s robust revenue growth as a positive signal. Some market reports noted pre-market strength in Insulet’s shares after the announcement, reflecting investor interest in the company’s performance and outlook.
Collectively, these developments have been described by market participants as supporting a positive outlook for Insulet heading into 2026, even as valuation multiples in its peer group have tightened.
Contextual note
The coverage reflects a mix of strong operational metrics and changing market valuation dynamics. Canaccord’s adjustment to its price target highlights the sensitivity of valuation to comparable-group multiples, while the company’s reported customer and revenue momentum and the list of product milestones remain central to investor assessments.